Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib safety endpoint study versus TNF inhibitor in rheumatoid arthritis
NL-OMON41518Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tofacitinib and etanercept in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoints: Adjudicated malignancies excluding non-melanoma skin cancers and Adjudicated major adverse cardiovascular events. Started Oct 2015; status: active, not recruiting.
02
Drugs
tofacitinibetanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41518.